Innoviva
INVA

Innoviva (INVA) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
OppenheimerInitiated CoverageOutperform$35.00Sep 23, 2026
Cantor FitzgeraldMaintainedOverweight$34.00 from $36.00Aug 7, 2026
BTIGMaintainedBuy$42.00Jun 22, 2026
HC Wainwright & Co.MaintainedBuy$46.00Jun 1, 2026
BTIGMaintainedBuy$42.00May 26, 2026
BTIGMaintainedBuy$42.00 from $35.00May 7, 2026
BTIGMaintainedBuy$35.00Feb 26, 2026
BTIGInitiated CoverageBuy$35.00Feb 17, 2026
HC Wainwright & Co.MaintainedBuy$46.00 from $45.00Dec 16, 2025
Cantor FitzgeraldMaintainedOverweight$31.00 from $29.00Nov 6, 2025
Goldman SachsInitiated CoverageSell$17.00Sep 30, 2025
HC Wainwright & Co.MaintainedBuy$45.00 from $40.00Aug 11, 2025
OppenheimerInitiated CoverageOutperform$35.00Aug 11, 2025
HC Wainwright & Co.Initiated CoverageBuy$40.00Jul 14, 2025
Cantor FitzgeraldInitiated CoverageOverweight$26.00Jul 11, 2025
ScotiabankInitiated CoverageSector Outperform$55.00Mar 7, 2025
Cantor FitzgeraldMaintainedOverweight—Aug 1, 2024
Cantor FitzgeraldMaintainedOverweight—Jul 30, 2024
Cantor FitzgeraldMaintainedOverweight—Jun 20, 2024
Cantor FitzgeraldInitiated CoverageOverweight—Jun 18, 2024

Frequently asked questions

  • What is the latest analyst rating on INVA?

    On Sep 23, 2026, Oppenheimer initiated coverage of Innoviva at Outperform with a price target of $35.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.